DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

**September 15, 2016**

**Department of Natural Resources, LaCharette/Nightengale Conference Room, Jefferson City, MO**

|  |  |
| --- | --- |
| **Committee Members Present**Conrad Balcer, D.OGene Forrester, R.Pharm D Laine Young-Walker, M.D.Morgan Sperry, Pharm DJennifer Kemp-Oestriech, Pharm DPatrick Bryant, Pharm D  | MO HealthNet Staff Present:Mark Roaseau, R.Ph, Clinical PharmacistStephen Calloway, R.Ph, Director of PharmacyJenna McTeer, RNAngela Wilson, Manager, Band ILisa Smith, Medicaid SpecialistMegan Goldthrite, Administrative Office Support AssistantElizabeth Short, Medicaid SpecialistChristine Thompson, Fiscal Unit ManagerDr. Timothy Kling  |

**Contractors in Attendance:**

Katie Wilbers, Pharm D, Xerox

Josh Moore, Pharm D, Xerox

Luke Boehmer, Pharm D, Xerox

Rick Pope, Pharm D, Magellan

|  |
| --- |
| Others Attending: |
| Brian Strickland, GileadChet Steckler, PurdueLon Lowery, NovatisChad Stewart, Boehringer-IngelhrionJeff Knappen, AllerganEvan Rushing, AlkermesBruce Burkett, Hep C AllianceLuke Boehmer, XeroxJosh Moore, XeroxKatie Wilbers, Xerox | Chelsea Pendleton, WiproColleen McKay, Actelion PharmTom Peddicord, NovatisTrey Gardner, SilvergateMike Holvers, Sunovion PharmBrian Hocum, United Therapeutics Derek Bush, AONDon Hopper, Vitel TherapeuticsJim Baumann, PfizerDan DeZee, 25 Pharm | Michelle Poyear, GileadSheila Kreut, Vital RXTami Sova, UCBJennifer Stoffel, JanssenSierra Johnson, GileadTodd Herman, MerckMichael Ferrar, MerckCamille Kerr, AmgenStaci Underwood, AbbvieMike LaFend, Abbvie | Josephine Garcia-Ferrer, Actelion PharmGeri Roling, WiproMelissa Laurie, BMSLisa Tootle, BMSLinda Krueger, AcadiaDel Deem, Astra ZenecaRobert Robey, IndiviorStaci Lockhart, Abbvie |

Many names on the sign-in sheet were illegible. Sign-in sheet on file for review.

|  |  |
| --- | --- |
| **Welcome, Introductions and Opening Remarks** | Conrad Balcer, D.O., Acting Committee Chairman, called the meeting to order. Stephen Calloway announced that Gene Forrester retired from the board and they would be looking to fill the vacancy.  |
| **Minutes Approval**  | Minutes of the June 17, 2016 meeting were reviewed and approved. Gene Forrester moved to accept the meeting minutes. Morgan Sperry seconded the motion. (See Roll Call Vote) |
| **Pharmacy Program/Budget Update** | Christine Thompson presented a brief slideshow. The presentation contained graphs representing an expenditure amount per member for all eligible participants, disabled participants, elderly participants, and other; a pie chart of participants; and expenditures by participants. |
| **DUR Report** | Stephen Calloway stated all items from the July DUR Meeting were ratified and are scheduled to be implemented the 4th quarter of 2016.  |
| **Old Business** |
| **Implementation Schedule**  | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members’ meeting packet and provided as a handout to all attending. The schedule included the therapeutic classes will be implemented January 2017. PDL decisions from September/October will be implemented January 2017. Schedules may be found on the MHD web page at <http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf>  |
| **New Business** |
| **New Drug Review** | Stephen Calloway reviewed the new drug products that were identified for the quarter April, May, June 2016 and the recommended status within the clinical program.**• Discussion –** A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending. **• Public Hearing –** Tami Sova from UCB/CNS provided information on Briviact. **• Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote) |

|  |
| --- |
| **Clinical Edits** |
| **Short-Acting Narcotics Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria. Mark Roseau and Conrad Balcer had a conversation regarding denial criteria. **• Public Hearing –** No comments entered.**• Decision –** After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| **Short-Acting Combination Narcotics Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this clinical edit as presented. (See Roll Call Vote) |
| **Opiate Reversal Agents Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this clinical edit as presented. (See Roll Call Vote) |
| **Preferred Drug List (PDL)** |
| **ACE Inhibitor Agents** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **ACE Inhibitors/Calcium Channel Blocker Combination Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Trey Gardener from Silver Gate Pharmaceuticals provided information on Epaned**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Angiotensin Receptor Blocker Agents (ARB’s)** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Angiotensin Receptor Blocker/Diuretic Combination Agents** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Angiotensin Receptor/Calcium Channel Blocker Combination Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Anticoagulant Agents: Oral and Subcutaneous** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Jennifer Stouffel from Jansen provided information on Xarelto**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Antiplatelet Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Beta Adrenergic Blockers and Diuretic Combination Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Calcium Channel Blocker Agents (Dihydropyridines)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Calcium Channel Blocker Agents (Non-Dihydropyridines)** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Direct Renin Inhibitors and Combination Agents** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Hepatitis C Therapy: Direct-Acting Antiviral Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Stacy Lockhart and Stacy Underwood from Abbvie provided information on Viekira and Viekira XR, Michele Puyear from Gilead provided information on Harvoni, Malissa Lauri from BMS provided information on Daklinza, Michael Ferari from Merck gave back his time form Zepitir, Bruce Burkett a Hepatitis C affiliate gave general Hepatitis C information. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Homozygous Familial Hypercholesterolemia Products** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Lipotropic Agents: Niacin and Combination Preparations** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Proton Pump Inhibitor Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Pulmonary Hypertension Agents: Inhaled/Injectable** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** Brian Hocum from United Therapeutics provided information on Orentiram. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Pulmonary Hypertension Agents: Oral** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Sympatholytic Antihypertensive Agents** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Triglyceride Lowering Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Proposed New Preferred Drug Classes** |  |
| **Preferred Drug List Announcement** | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.  |
|  |  |
| **Xerox Update** | Luke Boehmer, PharmD reviewed clinical edits, utilization data and trends for ADHD. Also, spoke about the different reasons for denials.  |
| **Program Utilization:****Top 25 Drugs Summary** | Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 4th quarter 2015 and the 1st quarter 2016. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims. |
| **Call Center Statistics/****CyberAccess Reports** | A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess.  |
| **Adjourn** | The meeting was adjourned. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, **December 15, 2016** at the **James C. Kirkpatrick State information Center, 600 W Main Street, Room 139**. Attendees were advised to check the [calendar of events](http://www.dss.mo.gov/mhd/global/pages/calendar.htm) on the MHD website for meeting location changes over the next few months. (See attached roll call) |

**Roll Call Votes – September 15, 2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **Minutes** | **New Drug Review** | **Short-Acting Narcotics Clinical Edit** | **Short-Acting Combination Narcotics Clinical Edit** | **Opiate Reversal Agents Clinical Edit** | **ACE Inhibitor Agents** | **ACE Inhibitors/Calcium Channel Blocker Combination Agents** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** | Y |   |   |   |   |   |   |
| **Gene Forrester, R.Ph** | YM | YM | Y | Y2 | YM | Y | Y |
| **Laine Young-Walker, M.D.** | Y2 | Y2 | Y | YM | Y2 | YM | YM |
| **Morgan Sperry, Pharm D** | Y | Y | Y2 | Y | Y | Y2 | Y2 |
| **Jennifer Kepm-Oestrich** | Y | Y | YM | Y | Y | Y | Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **ACE Inhibitors/Diuretic Combination Agents** | **Angiotensin Receptor Blocker Agents**  | **Angiotensin Receptor Blocker/Diuretic Combination Agents** | **Angiotensin iiReceptor/Calcium Channel Blocker Combination Agents** | **Anticoagulant Agents: Oral and Subcutaneous** | **Antiplatelet Agents** | **Beta Adrenergic Blockers and Diuretic Combination Agents** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** |   |   |   |   |   |   |   |
| **Gene Forrester, R.Ph** | YM | Y | YM | YM | Y | YM | YM |
| **Laine Young-Walker, M.D.** | Y | YM | Y | Y | Y | Y | Y |
| **Morgan Sperry, Pharm D** | Y | Y | Y | Y | Y2 | Y2 | Y2 |
| **Jennifer Kepm-Oestrich** | Y2 | Y2 | Y2 | Y2 | YM | Y | Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Calcium Channel Blocker Agents (Dihydropyridines)** | **Calcium Channel Blocker Agents (Non-Dihydropyridines)** | **Direct Renin Inhibitors and Combination Agents** | **Hepatitis C Therapy: Direct-Acting Antiviral Agents** | **Homozygous Familial Hypercholesterolemia Products** | **Lipotropic Agents: Niacin and Combination Preparations** | **Lipotropic Agents: Statins and Statin Combination Products** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** |   |   |   |   |   |   |   |
| **Gene Forrester, R.Ph** | YM | YM | YM | Y2 | Y | YM | Y |
| **Laine Young-Walker, M.D.** | Y | Y | Y2 | Y | Y2 | Y | Y2 |
| **Morgan Sperry, Pharm D** | Y | Y | Y | Y | Y | Y | YM |
| **Jennifer Kepm-Oestrich** | Y2 | Y2 | Y | YM | YM | Y2 | Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Proton Pump Inhibitor Agents** | **Pulmonary Hypertension Agents: Inhaled/Injectable** | **Pulmonary Hypertension Agents: Oral** | **Sympatholytic Antihypertensive Agents** | **Triglyceride Lowering Agents** | **Adjorn** |  |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y |   |
| **Pat Bryant, Pharm D** |   |   |   |   |   |   |   |
| **Gene Forrester, R.Ph** | YM | YM | YM | Y | Y | Y |   |
| **Laine Young-Walker, M.D.** | Y | Y | Y2 | Y | Y2 | Y |   |
| **Morgan Sperry, Pharm D** | Y | Y | Y | Y2 | YM | Y |   |
| **Jennifer Kepm-Oestrich** | Y2 | 2 | Y | YM | Y | Y |   |